Moxidectin
Names
[ CAS No. ]:
113507-06-5
[ Name ]:
Moxidectin
[Synonym ]:
Equest
Vetdectin Oral Drench
(1'R,2R,4E,4'S,5S,6S,8'R,10'E,13'R,14'E,16'E,20'R,21'R,24'S)-21',24'-Dihydroxy-4-(methoxyimino)-5,11',13',22'-tetramethyl-6-[(2E)-4-methyl-2-penten-2-yl]-3,4,5,6-tetrahydro-2'H-spiro[pyran-2,6'-[3,7,1 ;9]trioxatetracyclo[15.6.1.1.0]pentacosa[10,14,16,22]tetraen]-2'-one
proheart
bridged fused ring systems nomenclature: (2aE,4E,8E)-(5’S,6R,6’S,11R,13R,15S,17aR,20R,20aR,20bS)-6’-[(1E)-1,3-dimethylbut-1-enyl]-5’,6’,10,11,14,15,17a,20,20a,20b-decahydro-20,20b-dihydroxy-5’,6,8,19-tetramethylspiro[11,15-methano-2H,13H,17H-furo[4,3,2-pq][2,6]benzodioxacyclooctadecin-13,2’-[2H]pyran]-4’,17(3’H,6H)-dione 4’-(E)-(O-methyloxime)
ProHeart 6
Moxidectin HOUSE STANDARD
Moxidectin
(6R,23E,25S)-5-O-demethyl-28-deoxy-25-[(1E)-1,3-dimethyl-1-butenyl]-6,28-epoxy-23-(methoxyimino)milbemycin B
Quest
extended von Baeyer nomenclature: (10E,14E,16E)-(1R,4S,5’S,6R,6’S,8R,13R,20R,21R,24S)-6’-[(1E)-1,3-dimethylbut-1-enyl]-21,24-dihydroxy-5’,11,13,22-tetramethyl-(3,7,19-trioxatetracyclo[15.6.1.14,8.020,24]pentacosa-10,14,16,22-tetraene)-6-spiro-2’-(tetrahydropyran)-2,4’-dione 4’-(E)-(O-methyloxime)
Biological Activity
[Description]:
[Related Catalog]:
[References]
[Related Small Molecules]
Chemical & Physical Properties
[ Density]:
1.2±0.1 g/cm3
[ Boiling Point ]:
790.0±70.0 °C at 760 mmHg
[ Melting Point ]:
132 °C
[ Molecular Formula ]:
C37H53NO8
[ Molecular Weight ]:
639.819
[ Flash Point ]:
431.6±35.7 °C
[ Exact Mass ]:
639.377136
[ PSA ]:
116.04000
[ LogP ]:
8.43
[ Vapour Pressure ]:
0.0±6.2 mmHg at 25°C
[ Index of Refraction ]:
1.581
[ Storage condition ]:
2-8°C
Safety Information
[ Symbol ]:
GHS06, GHS09
[ Signal Word ]:
Danger
[ Hazard Statements ]:
H301-H400
[ Precautionary Statements ]:
Missing Phrase - N15.00950417
[ Personal Protective Equipment ]:
Eyeshields;Faceshields;Gloves;type P2 (EN 143) respirator cartridges
[ Hazard Codes ]:
T,N
[ Risk Phrases ]:
25-50
[ Safety Phrases ]:
45-61-24/25
[ RIDADR ]:
UN 2588
[ RTECS ]:
PY5438800
[ Packaging Group ]:
III
[ Hazard Class ]:
6.1(b)
[ HS Code ]:
29322090
Synthetic Route
Articles
Int. J. Parasitol. Drugs Drug Resist. 4(3) , 233-43, (2014)
A major hindrance to evaluating nematode populations for anthelmintic resistance, as well as for screening existing drugs, new compounds, or bioactive plant extracts for anthelmintic properties, is th...
In-vitro activity of avermectins against Mycobacterium ulcerans.PLoS Negl. Trop. Dis. 9(3) , e0003549, (2015)
Mycobacterium ulcerans causes Buruli ulcer (BU), a debilitating infection of subcutaneous tissue. There is a WHO-recommended antibiotic treatment requiring an 8-week course of streptomycin and rifampi...
The river blindness drug Ivermectin and related macrocyclic lactones inhibit WNT-TCF pathway responses in human cancer.EMBO Mol. Med. 6(10) , 1263-78, (2014)
Constitutive activation of canonical WNT-TCF signaling is implicated in multiple diseases, including intestine and lung cancers, but there are no WNT-TCF antagonists in clinical use. We have performed...